NCT02344017View on ClinicalTrials.gov

Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions

Prostate Cancer

Interventions

DRUG

ODM-204

co-administered with prednisone, orally daily

DRUG

Prednisone

ODM-204 is co-administered with oral prednisone

Trial Locations (4)

Unknown

Helsinki University Central Hospital, Helsinki

Institut Gustave Roussy, Villejuif

P. Stradins Clinical University Hospital, Riga

Velindre Cancer Centre, Cardiff

All Listed Sponsors

lead

Orion Corporation, Orion Pharma

INDUSTRY

NCT02344017 - Safety and Pharmacokinetics of ODM-204 in Patients With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter